Drug substitution in transplantation: a National Kidney Foundation White Paper (Q33534332)

27 July 2017

1 reference

title

Drug substitution in transplantation: a National Kidney Foundation White Paper (English)

1 reference

27 July 2017

1 reference

Sabatini S

1

1 reference

27 July 2017

Ferguson RM

2

1 reference

27 July 2017

Helderman JH

3

1 reference

27 July 2017

Hull AR

4

1 reference

27 July 2017

Kirkpatrick BS

5

1 reference

27 July 2017

Barr WH

6

1 reference

27 July 2017

publication date

1 February 1999

1 reference

American Journal of Kidney Diseases

27 July 2017

published in

1 reference

27 July 2017

volume

33

1 reference

27 July 2017

issue

2

1 reference

27 July 2017

page(s)

389-397

1 reference

Bioequivalence assessment of generic drugs: an American point of view

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

What are narrow therapeutic index drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Generic drug substitution revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Bioequivalence and generic prescribing: an industrial view

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

FDA position on product selection for ‘narrow therapeutic index’ drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Bioinequivalence and drug toxicity. How great is the problem and what can be done?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Effects of food on the bioequivalence of different verapamil sustained-release formulations.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Generic bioequivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

The Pharmacokinetics and Pharmacodynamics of Immunosuppressive Agents

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Switching Between Cyclosporin Formulations What are the Risks?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Optimizing the use of cyclosporine in renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

Factors Influencing the Pharmacokinetics of Cyclosporine in Man

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

A National Bill of Patients' Rights

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2899%2970318-5

7 January 2021

10.1016/S0272-6386(99)70318-5

Identifiers

DOI

1 reference

27 July 2017

1 reference